Major Brand-Name Formulations of Carbidopa-Levodopa
The major brand-name formulations of carbidopa-levodopa currently available include Sinemet (immediate-release), Sinemet CR (controlled-release), Rytary/Numient (extended-release capsules), Duodopa/Duopa (intestinal gel), and Stalevo (combination with entacapone) 1, 2, 3, 4.
Oral Formulations
Immediate-Release Products
- Sinemet: The original immediate-release formulation, reaching peak concentrations at 1 hour with rapid decline to <10% of peak by 5 hours 2
- Generic carbidopa-levodopa tablets are widely available in multiple strengths (10/100 mg, 25/100 mg, 25/250 mg) 5
Extended-Release Oral Products
- Sinemet CR: Sustained-release formulation with peak at 1.5 hours and concentrations maintained until 6.3 hours 2
- Rytary (US)/Numient (EU) (also known as IPX066): Novel extended-release capsule formulation containing beads designed to release at different rates, providing therapeutic concentrations for 4-5 hours with initial peak at approximately 1 hour 1, 2. This formulation demonstrated superior reduction in daily 'off-time' compared to immediate-release carbidopa-levodopa in phase III trials 1
- IPX203: A newer extended-release oral formulation currently in development 6, 7
Combination Products
- Stalevo: Combines carbidopa-levodopa with entacapone (COMT inhibitor) in a single tablet (25/100/200 mg), with peak concentrations at 1.5 hours and sustained levels until 7.5 hours 2, 4
Infusion Therapies
Intestinal Gel
- Duodopa (EU)/Duopa (US): Levodopa-carbidopa enteral suspension delivered directly into the proximal jejunum via PEG-J tube through a portable infusion pump 3, 8. This formulation overcomes fluctuating plasma concentrations and maintains steady levodopa levels 8. It is approved for advanced levodopa-responsive Parkinson's disease with severe motor fluctuations when oral combinations have failed 3
Subcutaneous Formulations (In Development)
- ND0612: Proprietary liquid formulation for subcutaneous administration via patch-pump device 4, 9
- Foslevodopa/foscarbidopa: Subcutaneous levodopa delivery system that has shown efficacy in reducing 'off' time in randomized trials 6, 9
Inhalation Products
- CVT-301: Levodopa inhalation powder with rapid onset of action, currently in active studies 4
Key Clinical Considerations
The choice between formulations depends on disease stage and symptom control needs. Multiple formulations exist because there are different pharmacokinetic and absorption profiles for each 10. The guidelines emphasize that formulation changes during hospitalization should be avoided when possible, as inadvertent substitutions can lead to missed or inaccurate dosing, medication errors, and clinical deterioration 10. When formulation changes are necessary (e.g., for swallowing difficulties), clinical pharmacists or neurologists should be involved to ensure appropriate dosing adjustments 10.
The extended-release formulations (Rytary/IPX066) provide more stable plasma concentrations with reduced peak-trough fluctuation compared to immediate-release products, while maintaining rapid onset 1, 2. For advanced disease with motor fluctuations not controlled by oral therapy, infusion therapies like Duodopa provide the most continuous delivery 3, 9.